RxDoctor Payments Data

Robert Musni, MD

Family Medicine · Las Vegas, NVNPI 1518969187

Payments from drug & device makers

$1,388in general payments, 2019–2025

Across 86 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$360
  • Boehringer Ingelheim$328
  • AstraZeneca$216
  • Pfizer$173
  • Johnson & Johnson$138
  • GSK$63
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$1,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,388 in reported general payments places this provider in the 70th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$18,327
Medicare patients
80
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$170,672
OzempicSemaglutide99$116,117
TradjentaLinagliptin44$65,293
JardianceEmpagliflozin32$61,859
Spiriva RespimatTiotropium Bromide69$56,642
XareltoRivaroxaban40$47,923
TrulicityDulaglutide18$25,730
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,686
MounjaroTirzepatide12$19,081
JanuviaSitagliptin Phosphate11$15,562
Atorvastatin Calcium1,273$12,635
LinzessLinaclotide20$12,528
SymbicortBudesonide/Formoterol Fumarate31$9,570
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$7,830
Omeprazole235$5,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat$328$183,794145 claims
PfizerEliquis$173$170,672148 claims
Novo NordiskOzempic$360$116,11799 claims
Johnson & JohnsonXarelto$138$47,92340 claims
GSKTrelegy Ellipta$63$21,68619 claims
MerckJanuvia$11$15,56211 claims
AstraZenecaSymbicort$216$9,57031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →